查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589597

藥物和基因輸送設備市場：按給藥途徑、方法和載體分類 - 全球預測 2025-2030

Drug & Gene Delivery Devices Market by Route of Administration (Inhalation, Injectable, Nasal), Method (Ex vivo, In situ), Vector - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年藥物和基因輸送設備市值為43.3億美元，預計到2024年將達到47.9億美元，複合年成長率為10.72%，到2030年將達到88.3億美元。

藥物和基因傳遞設備市場包括各種用於將藥物化合物或遺傳物質直接輸送到患者體內的系統，以最小的副作用實現標靶治療。未來的前景在於精準醫學的進步，這些設備在慢性病和遺傳性疾病的個人化治療中發揮著至關重要的作用。慢性病和遺傳疾病的日益普及以及對微創輸送技術的日益重視推動了對這些醫療設備的需求。應用因治療領域而異，例如癌症、糖尿病和感染疾病，最終用途包括醫院、診所和居家醫療。影響市場的主要成長要素包括生物技術的進步、對生技藥品不斷成長的需求以及提高給藥效率和患者依從性的奈米技術創新。最近的發展表明，開發生物分解性的智慧型藥物傳輸系統具有潛在的機會，這些系統可響應生理條件進行控制釋放。

主要市場統計
基準年[2023] 43.3億美元
預測年份 [2024] 47.9億美元
預測年份 [2030] 88.3億美元
複合年成長率（%） 10.72%

挑戰包括監管障礙、高開發成本和潛在的生物相容性問題。此外，我們也受到關鍵藥品專利到期和嚴格的品管要求的限制。市場競爭激烈，有大量的研發機會專注於改善遞送機制，例如用於基因轉移的微針、水凝膠和非病毒載體。鼓勵相關人員投資最尖端科技和跨行業合作，以改善設備功能和患者治療效果。為了利用新機遇，公司可以探索夥伴關係，利用人工智慧和巨量資料分析來改善個人化交付系統。創新最好集中在整合診斷和治療能力的多功能輸送平台上，從而提高療效和患者依從性。精準醫學和生技藥品不斷發展的格局需要持續的研究和創新，為策略市場切入點和持續的業務成長鋪平道路。

市場動態：快速發展的藥物和基因輸送設備市場的關鍵市場洞察

藥物和基因輸送設備市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 心血管疾病 (CVD) 和文明病的盛行率上升
    • 自動注射器和先進肺部設備簡介
    • 藥品和治療藥物的消費量增加
  • 市場限制因素
    • 併發症增加，提供治療和藥物所需的專業知識
  • 市場機會
    • 藥物傳遞和基因傳遞系統領域的進展，包括智慧奈米顆粒技術、脂質體和水凝膠以及3D列印
    • 持續增加基因組學領域的研究和開發，以開發基因傳遞系統
  • 市場挑戰
    • 高階產品成本增加

波特五力：駕馭藥物與基因傳遞設備市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解藥物和基因輸送設備市場的外部影響

外部宏觀環境因素在塑造藥物和基因傳遞設備市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解藥物和基因輸送設備市場的競爭格局

藥物和基因輸送設備市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣藥物和基因傳輸設備市場供應商的績效評估

FPNV 定位矩陣是評估藥物和基因傳遞設備市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，以規劃藥物和基因輸送設備市場的成功之路

藥物和基因輸送設備市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 心血管疾病 (CVD) 和文明病的盛行率上升
      • 自動注射器和先進肺部裝置簡介
      • 藥品和治療藥物的消費量增加
    • 抑制因素
      • 提供治療和藥物所需的複雜性和專業知識不斷增加
    • 機會
      • 智慧奈米顆粒技術、脂質體和水凝膠以及3D列印等藥物和基因傳遞系統領域的進展
      • 持續增加基因組學領域的研究和開發，以開發基因傳遞系統
    • 任務
      • 奢侈品成本上漲
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 藥物與基因遞送設備市場：依管理途徑

  • 吸入
  • 可注射的
  • 鼻腔
  • 眼科
  • 口服
  • 話題
  • 經皮

第7章藥物和基因遞送設備市場：依方法

  • 體外
  • 當地的

第 8 章藥物與基因遞送設備市場載體

  • 非病毒性
  • 病毒性的

第9章美洲藥物與基因傳遞設備市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太藥物與基因傳遞設備市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲/中東/非洲藥物與基因傳遞設備市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 3M Company
  • Antares Pharma, Inc.
  • B. Braun SE
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Eisai Co., Ltd.
  • Enable Injections, Inc.
  • Gerresheimer AG
  • Insulet Corporation
  • Johnson & Johnson Services Inc.
  • Koninklijke Philips NV
  • Merck KGaA
  • OraSure Technologies, Inc.
  • Oxford BioMedica PLC
  • Sanofi SA
Product Code: MRR-A86604082727

The Drug & Gene Delivery Devices Market was valued at USD 4.33 billion in 2023, expected to reach USD 4.79 billion in 2024, and is projected to grow at a CAGR of 10.72%, to USD 8.83 billion by 2030.

The market for Drug & Gene Delivery Devices encompasses a wide range of systems used to deliver pharmaceutical compounds and genetic materials directly into a patient's system, ensuring targeted therapy with minimal side effects. Future scope lies in advancing precision medicine, where these devices could become pivotal in personalized treatments for chronic and genetic diseases. The necessity for these devices stems from the growing prevalence of chronic and genetic disorders and an increasing emphasis on minimally invasive delivery techniques. Applications vary across therapeutic areas, including oncology, diabetes, and infections, with end-use segments covering hospitals, clinics, and home care settings. Key growth factors influencing the market include advancements in biotechnology, growing demand for biologics, and innovations in nanotechnology which enhance delivery efficacy and patient compliance. Recent trends suggest potential opportunities in developing biodegradable and smart drug delivery systems that respond to physiological conditions for controlled release.

KEY MARKET STATISTICS
Base Year [2023] USD 4.33 billion
Estimated Year [2024] USD 4.79 billion
Forecast Year [2030] USD 8.83 billion
CAGR (%) 10.72%

Challenges include regulatory hurdles, high development costs, and potential biocompatibility issues. Limitations are further imposed by patent expirations of major drugs and stringent quality control requirements. The market exhibits a competitive nature, with substantial opportunities in research and development focused on improving delivery mechanisms such as micro-needles, hydrogels, and non-viral vectors for gene delivery. Stakeholders are encouraged to invest in cutting-edge technologies and cross-industry collaborations to enhance device functionality and patient outcomes. To capitalize on emerging opportunities, firms can explore partnerships for leveraging AI and big data analytics in improving personalized delivery systems. Innovations are best focused on multifunctional delivery platforms that integrate diagnostics and therapeutic functions, thereby strengthening efficacy and patient adherence. The evolving landscape in precision medicine and biologics demands continuous research and innovation, paving the way for strategic market entry points and sustained business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug & Gene Delivery Devices Market

The Drug & Gene Delivery Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence rate of cardiovascular disorders (CVDs) and lifestyle disorders
    • Introduction of auto-injectors and advanced pulmonary devices
    • Rise in the consumption of drugs and therapeutic pharmaceuticals
  • Market Restraints
    • Increase in complications and expertise required in delivering therapeutics and drugs
  • Market Opportunities
    • Advancements in the field of drug and gene delivery systems such as smart nanoparticle technology, liposomes & hydrogels, and three-dimensional printing
    • Increasing ongoing research and development in the field of genomics for the development of gene delivery systems
  • Market Challenges
    • Increasing cost of high-end products

Porter's Five Forces: A Strategic Tool for Navigating the Drug & Gene Delivery Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug & Gene Delivery Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug & Gene Delivery Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug & Gene Delivery Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug & Gene Delivery Devices Market

A detailed market share analysis in the Drug & Gene Delivery Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug & Gene Delivery Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug & Gene Delivery Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug & Gene Delivery Devices Market

A strategic analysis of the Drug & Gene Delivery Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug & Gene Delivery Devices Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Antares Pharma, Inc., B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, Eisai Co., Ltd., Enable Injections, Inc., Gerresheimer AG, Insulet Corporation, Johnson & Johnson Services Inc., Koninklijke Philips N.V., Merck KGaA, OraSure Technologies, Inc., Oxford BioMedica PLC, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Drug & Gene Delivery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Inhalation, Injectable, Nasal, Ocular, Oral, Topical, and Transdermal.
  • Based on Method, market is studied across Ex vivo and In situ.
  • Based on Vector, market is studied across Non-viral and Viral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence rate of cardiovascular disorders (CVDs) and lifestyle disorders
      • 5.1.1.2. Introduction of auto-injectors and advanced pulmonary devices
      • 5.1.1.3. Rise in the consumption of drugs and therapeutic pharmaceuticals
    • 5.1.2. Restraints
      • 5.1.2.1. Increase in complications and expertise required in delivering therapeutics and drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the field of drug and gene delivery systems such as smart nanoparticle technology, liposomes & hydrogels, and three-dimensional printing
      • 5.1.3.2. Increasing ongoing research and development in the field of genomics for the development of gene delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Increasing cost of high-end products
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug & Gene Delivery Devices Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Inhalation
  • 6.3. Injectable
  • 6.4. Nasal
  • 6.5. Ocular
  • 6.6. Oral
  • 6.7. Topical
  • 6.8. Transdermal

7. Drug & Gene Delivery Devices Market, by Method

  • 7.1. Introduction
  • 7.2. Ex vivo
  • 7.3. In situ

8. Drug & Gene Delivery Devices Market, by Vector

  • 8.1. Introduction
  • 8.2. Non-viral
  • 8.3. Viral

9. Americas Drug & Gene Delivery Devices Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Drug & Gene Delivery Devices Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Drug & Gene Delivery Devices Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. Antares Pharma, Inc.
  • 3. B. Braun SE
  • 4. Baxter International Inc.
  • 5. Becton, Dickinson and Company
  • 6. Eisai Co., Ltd.
  • 7. Enable Injections, Inc.
  • 8. Gerresheimer AG
  • 9. Insulet Corporation
  • 10. Johnson & Johnson Services Inc.
  • 11. Koninklijke Philips N.V.
  • 12. Merck KGaA
  • 13. OraSure Technologies, Inc.
  • 14. Oxford BioMedica PLC
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. DRUG & GENE DELIVERY DEVICES MARKET RESEARCH PROCESS
  • FIGURE 2. DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRUG & GENE DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRUG & GENE DELIVERY DEVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY OCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY IN SITU, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 148. DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023